-
The Michael J. Fox Foundation for Parkinson’s Research Announces Study to Measure Parkinson’s Protein throughout Body
March 16, 2016
… the observational Systemic Synuclein Sampling Study (S4) to investigate the protein alpha-synuclein as a biomarker of … promising Parkinson’s biomarker candidate as it has been shown to aggregate in the brain cells of individuals with PD. … and peripheral tissues in a single individual.” By comprehensively studying both intrapersonal and …
-
Use of HspB1 Chaperone to Inhibit Pathological Alpha-synuclein Aggregation
… their safeguarding capacity is apparently not enough to protect against Parkinson disease. Increasing cellular … and absence of chaperones as well as control proteins to compare the efficiency of the studied chaperone systems. In … The increase of chaperone production by drugs has been shown in the literature. Upregulation of cellular chaperone …
-
Answers to More Attendee Questions from our Genetics and Parkinson’s Disease Webinar
October 30, 2013
… “Genetics and Parkinson’s Disease” Webinar—part of our Hot Topics in Parkinson's Disease Research Seminar Series—had a … general, most cases of Parkinson’s probably result from a combination of genetic and environmental triggers. Research … that could benefit everyone with the disease. Here’s how: Genes are little more than genetic recipes that our …
-
Michael J. Fox Foundation CEO Deborah W. Brooks and Patient Council Member Israel Robledo Appointed to Federal Advisory Council to Guide First-Ever U.S. Parkinson’s Strategy
April 10, 2026
… Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced that its Chief Executive Officer and … implementation of the National Parkinson’s Project (NPP), a comprehensive national strategy to end Parkinson’s disease … J. Fox Foundation, while a new national voter survey shows strong bipartisan support for increased federal action …
-
Development of Inhibitors of Alpha-Synuclein Toxicity to Treat Parkinson's Disease
… Objective/Rationale: Many of the symptoms of Parkinson’s disease are caused by the death of … Using novel cellular assays, we have discovered lead compounds that prevent the toxicity induced by … disease progression. Anticipated Outcome: We expect to show that our lead compounds are efficacious as …
-
The New York Times: Seeking a Shorter Path to New Drugs
November 15, 2009
… cost $800 million or more, and takes more than eight years to research and develop? A new medicine, according to data … is no longer a sustainable model for big pharmaceutical companies. “We invest far too long in bad ideas,” Dr. Turner … with outside researchers on identifying novel “targets” — the disease pathways in the body that medicines are …